Start here if you're new
what it is
Precision BioSciences uses its ARCUS gene-editing tool to try to create one-time treatments for hard genetic and infectious diseases.
how it gets paid
Last year Precision Bioscience made $34M in revenue. platform collaborations was the main engine at $18M, or 53% of sales.
why growth slowed
Revenue fell 50.1% last year. The $60K quarter shows how little cash the business pulls in outside financing and milestone events.
what just happened
Quarterly revenue was $60K, while EPS came in at -$6.14.
At a glance
C+ balance sheet — struggling to keep the lights on
35/100 earnings predictability — expect surprises
-$3.26 fy2024 eps est
$69M fy2024 rev est
n/a operating margin
xvary composite: 23/100 — weak
What they do
Precision BioSciences uses its ARCUS gene-editing tool to try to create one-time treatments for hard genetic and infectious diseases.
ARCUS is smaller and simpler than many gene editors. That matters because you are backing a 108-person shop against much larger rivals. The edge is focus, but the quiet part is this: one platform has to carry the whole story until late-Q1 or early-Q2 2026.
How they make money
$34M
annual revenue · their business grew -50.1% last year
platform collaborations
$18M
in vivo gene editing
$8M
program support
$5M
other income
$3M
The products that matter
proprietary gene-editing platform
ARCUS Platform
pipeline foundation · implied value ~$24.4M beyond cash
this platform is the reason the market assigns any value beyond the $115.6M cash balance. At today's $140M market cap, ARCUS and the rest of the pipeline are being valued at roughly $24.4M.
cash-backed science
lead clinical pipeline asset
Hepatitis B program
targets ~300M patients globally
this is the program most likely to move the stock because the target population is roughly 300 million people. That is a massive market, which is exactly why the clinical risk matters so much.
binary catalyst
partner-funded business model
Collaboration revenue
$34.2M recent quarter · $69M fy2024 rev est
the business is still being financed by collaboration checks, not commercial drug sales. The recent $34.2M quarter looked healthy, but it does not answer the bigger question of eventual product economics.
not product revenue
Key numbers
-$3.26
fy2024 eps est
$69M
fy2024 rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $28M (16% of capital)
C+ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for DTIL right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Quarterly revenue was $60K, while EPS came in at -$6.14.
Revenue was up 362% vs. prior year, but from a tiny base. The loss widened 234% vs. prior year, so spending still outruns sales by a lot.
$0.06M
revenue
-$6.14
eps
n/a
n/a
the number that mattered
The $60K quarter shows how little cash the business pulls in outside financing and milestone events.
source: company earnings report
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is hepatitis B clinical failure on the ARCUS platform. That is the asset most likely to justify more than a cash-box valuation.
med
Clinical readouts disappoint
There is no approved product to fall back on. If the hepatitis B program fails to show convincing progress, the market is left staring at a $140M company whose main asset is cash, not commercial proof.
That would directly hit the roughly $24.4M of valuation currently assigned to the pipeline beyond cash.
med
Runway slips faster than expected
Management says cash runway extends through 2028, but clinical-stage burn rates can change quickly. The balance sheet is only a cushion if the timeline holds.
If runway guidance shortens, financing risk moves from background noise to the main story.
med
Collaboration revenue masks the real issue
The company posted $34.2M in recent revenue and a $69M full-year estimate, but that still reflects collaboration economics rather than product sales. Those dollars can make the numbers look healthier than the business model really is.
If collaboration flows fade before clinical value shows up, you are left with losses, volatility, and another capital raise conversation.
With $115.6M of cash against a $140M market cap, the valuation looks protected on the surface. The catch is simple: if the science slips or the 2028 runway claim weakens, the part you are actually underwriting gets smaller fast.
source: institutional data · regulatory filings · risk analysis
Pay attention to
clinical calendar
HBV program updates
The hepatitis B program is the lead proof point for ARCUS and addresses roughly 300 million patients globally. If you own DTIL, this is the calendar item that can change the entire debate.
balance sheet
Cash versus market cap
Today the company has $115.6M in cash against a $140M market cap. Watch that gap. It is the simplest way to tell whether the stock still trades like a pipeline option backed by cash.
revenue quality
Collaboration revenue trend
The latest quarterly revenue was $34.2M, while the collaboration line shown here is $34M and down 50.1%. You want to know whether partner funding is stabilizing or just buying time.
financing risk
Runway guidance through 2028
Management extended expected cash runway through 2028. If that language changes in a future update, the stock likely stops trading on optionality and starts trading on dilution risk.
Analyst rankings
earnings predictability
35 / 100
In human-speak: analysts do not have a clean model here because collaboration payments and clinical-stage expenses make the numbers jumpy.
risk profile
5 / 100
This sits near the bottom of the safety stack. Translation: expect volatility, financing sensitivity, and a market that reacts hard to small updates.
source: institutional data
Institutional activity
institutional ownership data for DTIL is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive